Immunovia AB (publ) (IMMNOV.ST)
SEK 0.66
(1.23%)
SEK 0.66
(1.23%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 98.68 Million SEK | -67.17% |
| 2022 | 300.58 Million SEK | -39.13% |
| 2021 | 493.8 Million SEK | -25.31% |
| 2020 | 661.17 Million SEK | 57.66% |
| 2019 | 419.36 Million SEK | -12.15% |
| 2018 | 477.38 Million SEK | 90.37% |
| 2017 | 250.76 Million SEK | -11.52% |
| 2016 | 283.4 Million SEK | 209.71% |
| 2015 | 91.5 Million SEK | 135.4% |
| 2014 | 38.87 Million SEK | 420.7% |
| 2013 | 7.46 Million SEK | 149.05% |
| 2012 | 2.99 Million SEK | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q1 | 71.02 Million SEK | -28.03% |
| 2024 Q2 | 58.26 Million SEK | -17.96% |
| 2023 Q4 | 98.68 Million SEK | -34.03% |
| 2023 FY | 98.68 Million SEK | -67.17% |
| 2023 Q1 | 253 Million SEK | -15.83% |
| 2023 Q2 | 190.1 Million SEK | -24.86% |
| 2023 Q3 | 149.59 Million SEK | -21.31% |
| 2022 FY | 300.58 Million SEK | -39.13% |
| 2022 Q4 | 300.58 Million SEK | -16.69% |
| 2022 Q3 | 360.79 Million SEK | -10.67% |
| 2022 Q2 | 403.89 Million SEK | -10.16% |
| 2022 Q1 | 449.54 Million SEK | -8.96% |
| 2021 Q2 | 599.98 Million SEK | -5.62% |
| 2021 Q3 | 551.79 Million SEK | -8.03% |
| 2021 Q4 | 493.8 Million SEK | -10.51% |
| 2021 FY | 493.8 Million SEK | -25.31% |
| 2021 Q1 | 635.68 Million SEK | -3.86% |
| 2020 Q4 | 661.17 Million SEK | -5.15% |
| 2020 FY | 661.17 Million SEK | 57.66% |
| 2020 Q3 | 697.08 Million SEK | -5.1% |
| 2020 Q2 | 734.55 Million SEK | 87.25% |
| 2020 Q1 | 392.28 Million SEK | -6.46% |
| 2019 Q2 | 461.57 Million SEK | -5.95% |
| 2019 Q1 | 490.75 Million SEK | 2.8% |
| 2019 FY | 419.36 Million SEK | -12.15% |
| 2019 Q4 | 419.36 Million SEK | -5.83% |
| 2019 Q3 | 445.34 Million SEK | -3.52% |
| 2018 Q4 | 477.38 Million SEK | -4.8% |
| 2018 Q2 | 526.2 Million SEK | 125.1% |
| 2018 Q3 | 501.42 Million SEK | -4.71% |
| 2018 FY | 477.38 Million SEK | 90.37% |
| 2018 Q1 | 233.76 Million SEK | -6.78% |
| 2017 Q1 | 276.43 Million SEK | -2.46% |
| 2017 Q2 | 268.54 Million SEK | -2.85% |
| 2017 Q3 | 260.2 Million SEK | -3.11% |
| 2017 Q4 | 250.76 Million SEK | -3.63% |
| 2017 FY | 250.76 Million SEK | -11.52% |
| 2016 Q2 | 84.32 Million SEK | 0.0% |
| 2016 Q1 | - SEK | -100.0% |
| 2016 FY | 283.4 Million SEK | 209.71% |
| 2016 Q4 | 283.4 Million SEK | 0.0% |
| 2015 Q3 | 91.5 Million SEK | 140.86% |
| 2015 Q1 | 37.99 Million SEK | -2.27% |
| 2015 Q4 | 91.5 Million SEK | 0.0% |
| 2015 FY | 91.5 Million SEK | 135.4% |
| 2015 Q2 | 37.99 Million SEK | 0.0% |
| 2014 Q1 | - SEK | 0.0% |
| 2014 Q4 | 38.87 Million SEK | 0.0% |
| 2014 FY | 38.87 Million SEK | 420.7% |
| 2014 Q3 | 38.87 Million SEK | 0.0% |
| 2013 FY | 7.46 Million SEK | 149.05% |
| 2012 FY | 2.99 Million SEK | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| AroCell AB (publ) | 174.89 Million SEK | 43.576% |
| Devyser Diagnostics AB (publ) | 510.1 Million SEK | 80.655% |
| Prostatype Genomics AB (publ) | 49.22 Million SEK | -100.481% |
| SenzaGen AB | 97.17 Million SEK | -1.549% |
| Spermosens AB | 26.1 Million SEK | -278.016% |